Calcitonin gene-related peptide modulates interleukin-13 in circulating cutaneous lymphocyte-associated antigen-positive T cells in patients with atopic dermatitis

Antúnez, C.; Torres, Mauricio; lópez, S. Sacristán; Rodríguez-Pena, Rebeca; Blanca, Miguel; Mayorga, Cristobalina; Santamaria‐Babí, Luis F.

doi:10.1111/j.1365-2133.2009.09318.x

Cited by 37 publications

(28 citation statements)

References 40 publications

(81 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Accordingly, this effect would lead to a decrease in inflammatory and pain mediators and therefore cannot explain the analgesic properties of CGRP receptor antagonist observed in our studies. Immune cells and neurons [2,43,74] express CGRP receptors. CGRP can be released by macrophages, and CGRP receptor antagonist can decrease the release of proinflammatory mediators from immune cells [47].…”

Section: Local Topical Application Of Bibn4096bs Reduces Wdr Neuronalmentioning

confidence: 99%

The CGRP receptor antagonist BIBN4096BS peripherally alleviates inflammatory pain in rats

Hirsch

Corradini

Just

et al. 2013

Pain

View full text Add to dashboard Cite

Calcitonin gene-related peptide (CGRP) is known to play a major role in the pathogenesis of pain syndromes, in particular migraine pain. Here we focus on its implication in a rat pain model of inflammation, induced by injection of complete Freund adjuvant (CFA). The nonpeptide CGRP receptor antagonist BIBN4096BS reduces migraine pain and trigeminal neuronal activity. Here we demonstrate that the compound reduces inflammatory pain and spinal neuronal activity. Behavioural experiments reveal a reversal of the CFA-induced mechanical hypersensitivity and monoiodoacetate (MIA)-induced weight-bearing deficit in rats after systemic drug administration. To further investigate the mechanism of action of the CGRP antagonist in inflammatory pain, in vivo electrophysiological studies were performed in CFA-injected rats. Recordings from wide dynamic range neurons in deep dorsal horn layers of the lumbar spinal cord confirmed a reduction of neuronal activity after systemic drug application. The same amount of reduction occurred after topical administration onto the paw, with resulting systemic plasma concentrations in the low nanomolar range. However, spinal administration of BIBN4096BS did not modify the neuronal activity in the CFA model. Peripheral blockade of CGRP receptors by BIBN4096BS significantly alleviates inflammatory pain.

show abstract

Section: Local Topical Application Of Bibn4096bs Reduces Wdr Neuronalmentioning

confidence: 99%

The CGRP receptor antagonist BIBN4096BS peripherally alleviates inflammatory pain in rats

Hirsch

Corradini

Just

et al. 2013

Pain

View full text Add to dashboard Cite

show abstract

“…While it is unclear what role CGRP plays in allergic conditions the peptide is markedly upregulated in the airways of atopic asthmatics during late-phase reactions provoked by inhalation of allergen-derived T-cell activating peptides [108]. Furthermore, the response of immune cells appears to alter in human subjects with allergic disease and/or inflammation.…”

Section: Calcitonin Gene Related Peptidementioning

confidence: 98%

The Nervous System as a Critical Regulator of Immune Responses Underlying Allergy

Forsythe¹

2012

CPD

View full text Add to dashboard Cite

The nervous and immune systems collaborate in the control of homeostasis and host defence. All divisions of the nervous system, sympathetic, parasympathetic and sensory, act to regulate immune cell function. Processes under neuronal control include antigen processing and presentation, Th1/Th2 balance, immunoglobulin production and antigen specific responses, while involvement of the central nervous system allows for behavioral changes leading to avoidance of antigen or noxious stimuli. It therefore follows that dysregulation of these complex bidirectional neuroimmune signaling systems may contribute to the aetiology and pathophysiology of immune disorders including atopic disease. A greater understanding on how the brain perceives, processes and responds to immune challenges and how multiple neurotransmitters interact to maintain or skew the balance between tolerance and immunity will undoubtedly provide opportunities for the development of novel therapeutics. Furthermore, the implications for atopic disease of relatively recent developments such as the cholinergic anti-inflammatory pathway and the potential direct antigen-specific activation of the nervous system require further exploration.

show abstract

“…Finally, other neurogenic mechanisms involve CLA + T cells in AD. Calcitonin gene-related peptide has been shown to directly activate CLA + T cells and increase IL-13 production in AD patients, [39] and mental stress in AD increased the number of CLA + T cells in circulation [40]. …”

Section: Circulating Cla+ T Cells Contain Subsets Of T Cells That Resmentioning

confidence: 99%

Pathological Mechanisms of Skin Homing T Cells in Atopic Dermatitis

Ferrán¹,

Santamaria‐Babí

2010

World Allergy Organization Journal

View full text Add to dashboard Cite

Skin infiltration of circulating memory T cells with cutaneous tropism is considered one of the pathologic mechanisms in atopic dermatitis (AD). Skin-seeking circulating T lymphocytes can be identified by their expression of the cutaneous lymphocyte-associated antigen on the cell surface. Recent studies have contributed useful new information about the function and recirculation properties of those cells in AD patients. This review integrates the latest findings on peripheral cutaneous lymphocyte-associated antigen memory T cells in AD and highlights the relevance of this cell type and its importance to our understanding of the pathologic mechanisms of AD.

show abstract

Calcitonin gene-related peptide modulates interleukin-13 in circulating cutaneous lymphocyte-associated antigen-positive T cells in patients with atopic dermatitis

Abstract: Our results suggest an immunomodulatory role of CGRP towards a Th2 pattern in CLA+ T cells, which may contribute to exacerbating clinical symptoms in patients with AD.

Cited by 37 publications

References 40 publications

The CGRP receptor antagonist BIBN4096BS peripherally alleviates inflammatory pain in rats

The CGRP receptor antagonist BIBN4096BS peripherally alleviates inflammatory pain in rats

The Nervous System as a Critical Regulator of Immune Responses Underlying Allergy

Pathological Mechanisms of Skin Homing T Cells in Atopic Dermatitis

Contact Info

Product

Resources

About